Difference between revisions of "Margetuximab (Margenza)"
m (→Also known as) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12 | + | *2020-12-16: Approved in combination with chemotherapy, for the treatment of adult patients with metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. ''(Based on SOPHIA)'' |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' MGA-H22 |
*'''Brand name:''' Margenza | *'''Brand name:''' Margenza | ||
Latest revision as of 12:53, 8 September 2023
Mechanism of action
From the NCI Drug Dictionary: A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B).
Diseases for which it is used
History of changes in FDA indication
- 2020-12-16: Approved in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Based on SOPHIA)
Also known as
- Code name: MGA-H22
- Brand name: Margenza